Piper Sandler Starts Perspective Therapeutics Inc (CATX) at Overweight

Piper Sandler analyst Biren Amin initiates coverage on Perspective Therapeutics Inc (NYSE: CATX) with a Overweight rating and a price target of $16.00.

The analyst comments: "We are initiating coverage on Perspective Therapeutics (CATX) with an Overweight rating and $16 PT. The company's pipeline of lead-212 radiotherapies harnesses alpha radiation (superior potency vs. beta-emitters) with a differentiated safety profile enabled by a proprietary net-neutral chelator. The lead asset VMT-α-NET targets SSTR2, with early dose-escalation data in NETs comparing favorably to SOC Lutathera (39% ORR vs. Lutathera's 13%). Critically, VMT-α-NET has reported zero serious renal events or dysphagia to date (TRAEs that likely led to AlphaMedix's recent deprioritization), highlighting the value of CATX's radiopharma platform. We model VMT-α-NET with ~$950M in risk-adjusted revenues. Near-term catalysts include mid-'26 and late '26 updates. Initial VMT01 + nivolumab combination data are expected mid-2026, and initial PSV-359 dose- escalation data (in tumor basket study) are guided to late '26."

For an analyst ratings summary and ratings history on Perspective Therapeutics Inc click here. For more ratings news on Perspective Therapeutics Inc click here.

Shares of Perspective Therapeutics Inc closed at $5.03 yesterday.

You May Also Be Interested In

• Ferguson Enterprises to Join S&P 500; ADI Global Distribution to Join S&P SmallCap 600
• US Critical Metals completes Arizona copper project acquisition
• Warner Music Group CFO and COO Armin Zerza steps down